Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcomes to the results of pivotal clinical trials CLEOPATRA and EMILIA.
Practice Patterns and Outcomes: doi.org/10.1001/jamaoncol.2021.2140
Back us on Patreon! www.patreon.com/plenarysession
Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew